Abstract

Staff att this office provide administrative coordination for all of the activities of ECOG, are responsible for protocol development, conducting all audits of member institutions, maintaining IRB and membership documentation, tracking publications, coordinating the semi-annual group meetings, and fiscal management. Effective May 1, 1995, the Operations Office moved to Frontier Science & Technology Research Foundation in Brookline, MA and combined of these two synthesis, and provides more comprehensive support to the Group. The Operations Office is able to meet the needs of the Group as it evolves, and will continue this effort in the next five years.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA021115-28S1
Application #
6664266
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1992-09-01
Project End
2004-04-30
Budget Start
2002-09-26
Budget End
2003-04-30
Support Year
28
Fiscal Year
2002
Total Cost
$220,820
Indirect Cost

  Institution

Name
Frontier Sci & Technology Rsch Fdn, Inc
Department
Type
DUNS #
080330186
City
Boston
State
MA
Country
United States
Zip Code
02215

  Publications

Ailawadhi, Sikander; Jacobus, Susanna; Sexton, Rachael et al. (2018) Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8:67
Lubner, Sam; Feng, Yang; Mulcahy, Mary et al. (2018) E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 23:1006-e104
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Francis, Prudence A; Pagani, Olivia; Fleming, Gini F et al. (2018) Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med 379:122-137
Lemieux, Julie; Brundage, Michael D; Parulekar, Wendy R et al. (2018) Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. J Clin Oncol 36:563-571
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Sparano, Joseph A; Gray, Robert; Oktay, Maja H et al. (2017) A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer. NPJ Breast Cancer 3:42
Saha, Poornima; Regan, Meredith M; Pagani, Olivia et al. (2017) Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol 35:3113-3122

Showing the most recent 10 out of 753 publications